Multimodality management for 145 cases of Merkel cell carcinoma

The results of the multimodality management of 145 cases of cutaneous Merkel cell carcinoma (MCC) are reported herein. Patient information was obtained from medical records of four Canadian institutions and one French institution. These data included ages, pathological stages, disease sites, histolo...

Full description

Saved in:
Bibliographic Details
Published in:Medical oncology (Northwood, London, England) London, England), 2010-12, Vol.27 (4), p.1260-1266
Main Authors: Tai, Patricia, Yu, Edward, Assouline, Avi, Lian, Ji Dong, Joseph, Kurian, Miale, Thomas, Krzisch, Claude
Format: Article
Language:English
Subjects:
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Carcinoma, Merkel Cell - pathology
Carcinoma, Merkel Cell - surgery
Carcinoma, Merkel Cell - therapy
Combined Modality Therapy
Female
Follow-Up Studies
Hematology
Humans
Internal Medicine
Male
Medicine
Medicine & Public Health
Middle Aged
Neoplasm Recurrence, Local - pathology
Neoplasm Recurrence, Local - surgery
Neoplasm Recurrence, Local - therapy
Neoplasm Staging
Oncology
Original Paper
Pathology
Prognosis
Radiotherapy Dosage
Skin Neoplasms - pathology
Skin Neoplasms - surgery
Skin Neoplasms - therapy
Survival Rate
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The results of the multimodality management of 145 cases of cutaneous Merkel cell carcinoma (MCC) are reported herein. Patient information was obtained from medical records of four Canadian institutions and one French institution. These data included ages, pathological stages, disease sites, histological and treatment details. Cause-specific survival (CSS), overall survival (OS) and disease-free survival (DFS) rates were analyzed by the log-rank and Kaplan-Meier methods. From 1988 to 2007, 145 cases were analyzed. There were 74 men and 71 women. Median age was 78 years (range 47–95.2). Median follow-up was 21.5 months (range 0.5–169.1). During the follow-up period, 37 local, 37 regional nodal and 15 distant recurrences were determined to be either solitary or multifocal sites of treatment failure. Relapsing patients were treated with multimodal treatments provided that their general state of health did not preclude this approach. Either initially and/or at relapse, 30 patients were treated with either multiagent (mostly etoposide with cisplatin or carboplatin) or single-agent chemotherapy, including irinotecan, taxotere and topotecan. In conclusion, recurrence should be treated with multimodalities. Our experience of long-term survivors after treatment of recurrence is encouraging.
ISSN:1357-0560
1559-131X
DOI:10.1007/s12032-009-9369-7